Biotech firm Antengene's H1 revenue jumps on licensing deals

Antengene

21/08/2026 11:38

Overview
Biotech company's H1 revenue rose sharply on licensing deals with UCB, K2 Therapeutics
Company swung to H1 net profit from loss a year earlier
Company repurchased 1.83 mln shares for HK$7.57 mln after reporting period

Outlook
Company is prioritizing development of ATG-022 and ATG-037 as key growth drivers
Antengene plans to file INDs for multiple preclinical candidates in 2027
Company aims to expand XPOVIO® (selinexor) market reach and reimbursement in Asia Pacific

Result Drivers
LICENSING DEALS - Revenue growth mainly driven by upfront payments from out-licensing agreements for ATG-201 and ATG-106 with UCB and K2 Therapeutics
HIGHER R+D COSTS - Increased research and development costs due to higher drug development expenses
LOWER ADMINISTRATIVE EXPENSES - Administrative expenses declined due to improved operational efficiency

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
H1 Revenue
 
RMB 513.1 mln
 
H1 Net Income Attributable
 
RMB 216.3 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Antengene Corp Ltd is HK$7.54, about 93% above its August 21 closing price of HK$3.91
The stock recently traded at 23 times the next 12-month earnings vs. a P/E of 18 three months ago

Reuters Recommended Reads
Aug 19 - China's Ascentage Pharma H1 revenue rises 29% on Lisaftoclax ramp-up
Aug 20 - China's Brii Biosciences interim net loss narrows on lower R&D expenses
Aug 20 - China's top drugmaker Hengrui sees profit growth squeezed by bulk-buying programs

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

Press Release s3://eap-prd-eu-west-1-source-content/eap_feed_proxy/fingerpost/HKSW/2026-08-21/f664f884-a0f2-40c5-9a63-5ce83acbd659.file
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)